ANDRE, FABRICE
 Distribuzione geografica
Continente #
NA - Nord America 113
EU - Europa 72
AS - Asia 45
SA - Sud America 10
AF - Africa 3
Totale 243
Nazione #
US - Stati Uniti d'America 113
DE - Germania 31
GB - Regno Unito 20
SG - Singapore 16
CN - Cina 12
BR - Brasile 7
HK - Hong Kong 5
SE - Svezia 5
VN - Vietnam 5
RU - Federazione Russa 4
FR - Francia 3
IT - Italia 3
UA - Ucraina 3
CO - Colombia 2
KR - Corea 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
FI - Finlandia 1
GA - Gabon 1
IN - India 1
JP - Giappone 1
NL - Olanda 1
PS - Palestinian Territory 1
TR - Turchia 1
Totale 243
Città #
Santa Clara 13
Southend 12
Ann Arbor 11
Singapore 10
Ashburn 9
Dearborn 9
Jacksonville 8
Dallas 6
San Jose 6
Chandler 5
Hong Kong 5
Nyköping 5
Beijing 4
Wilmington 4
Cambridge 3
Chicago 3
Falls Church 3
Ho Chi Minh City 3
Houston 3
London 3
Seattle 3
The Dalles 3
Woodbridge 3
Columbus 2
Fairfield 2
Hefei 2
Los Angeles 2
Milan 2
Seoul 2
Amsterdam 1
Bangalore 1
Barrancabermeja 1
Betim 1
Blumenau 1
Bogotá 1
Buffalo 1
Cape Town 1
Cidade Ocidental 1
City of London 1
Council Bluffs 1
Cubatão 1
Detroit 1
Duque de Caxias 1
Eugene 1
Hanoi 1
Johannesburg 1
Kunming 1
Lauterbourg 1
Libreville 1
Longview 1
Meriden 1
Nanjing 1
Newark 1
Princeton 1
Rio Brilhante 1
San Diego 1
Sofia 1
Sumaré 1
Tokyo 1
Totale 176
Nome #
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 245
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 1
Totale 246
Categoria #
all - tutte 872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 872


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 1 1
2021/202214 0 0 0 0 2 3 0 1 5 2 0 1
2022/202313 2 2 1 1 1 4 0 1 1 0 0 0
2023/20248 0 0 3 0 1 0 0 4 0 0 0 0
2024/202534 0 0 0 3 9 6 3 2 4 1 4 2
2025/202670 5 2 9 2 16 4 5 9 9 5 4 0
Totale 246